Insider Selling: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Sells 31,445 Shares of Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS) insider Preston Klassen sold 31,445 shares of the stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total value of $39,620.70. Following the completion of the sale, the insider now owns 36,055 shares of the company’s stock, valued at approximately $45,429.30. This trade represents a 46.59 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Regulus Therapeutics Trading Up 0.8 %

NASDAQ:RGLS opened at $1.28 on Friday. Regulus Therapeutics Inc. has a one year low of $1.08 and a one year high of $3.79. The business’s 50-day simple moving average is $1.52 and its 200 day simple moving average is $1.58.

Regulus Therapeutics (NASDAQ:RGLS) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.03). Sell-side analysts forecast that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Institutional Trading of Regulus Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. acquired a new position in Regulus Therapeutics during the 3rd quarter worth $1,403,000. NEA Management Company LLC bought a new position in shares of Regulus Therapeutics during the third quarter worth about $10,154,000. Barclays PLC grew its stake in Regulus Therapeutics by 285.2% in the third quarter. Barclays PLC now owns 84,477 shares of the biopharmaceutical company’s stock worth $132,000 after purchasing an additional 62,549 shares in the last quarter. State Street Corp increased its holdings in Regulus Therapeutics by 3.5% in the third quarter. State Street Corp now owns 1,000,998 shares of the biopharmaceutical company’s stock valued at $1,572,000 after buying an additional 33,496 shares during the last quarter. Finally, Victory Capital Management Inc. increased its holdings in Regulus Therapeutics by 10.4% in the third quarter. Victory Capital Management Inc. now owns 398,866 shares of the biopharmaceutical company’s stock valued at $626,000 after buying an additional 37,480 shares during the last quarter. 92.38% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Regulus Therapeutics in a research note on Monday, November 11th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.